MCAG Mountain Crest Acquisition Corp. V
- 10.650
- 0.0000.00%
Mountain Crest Acquisition Corp. V News
Mountain Crest Acqn V Agrees Terms With Cubebio Over Potential Business Combination >MCAG
Mountain Crest Acqn V Agrees Terms With Cubebio Over Potential Business Combination >MCAG
Express News | Cubebio Co., Ltd. Entered Into Terms Relating to a Potential Business Combination With Mountain Crest Acquisition Corp. V
Trading Halt: Halted at 8:55:00 A.m. ET - Trading Halt: Halt News Pending
Trading Halt: Halted at 8:55:00 A.m. ET - Trading Halt: Halt News Pending
Mountain Crest Acquisition Corp. V Announces Listing Transfer to the Nasdaq Capital Market
NEW YORK, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V (NASDAQ:MCAG) (the "Company") announced today that it has received approval from the Nasdaq Stock Market ("Nasdaq") to transfer the listing
AUM Biosciences Terminates Merger With SPAC Mountain Crest V
Short Interest in Mountain Crest Acquisition Corp. V (NASDAQ:MCAG) Decreases By 16.7%
Mountain Crest Acquisition Corp. V (NASDAQ:MCAG – Get Rating) was the recipient of a significant decrease in short interest during the month of February. As of February 28th, there was short interest
SPAC Mountain Crest III Shareholders Approve ETAO Merger
AUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma
SINGAPORE and BETHESDA, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. ("AUM"), a global clinical-stage biotech company focused on discovering and developing precision oncology therapeutics, announced
AUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of Neuroblastoma
SINGAPORE and BETHESDA, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. ("AUM"), a global clinical-stage biotech company focused on discovering and developing precision oncology therapeutics, announced
AUM Biosciences Receives Human Research Ethics Committee Approval To Commence Phase II Clinical Trial Of AUM001 For Treatment Of Metastatic Colorectal Cancer In Australia
AUM Biosciences Pte. Ltd. ("AUM"), a clinical-stage biotechnology company, advancing a clinical stage candidate and a broader pipeline designed to deploy multi-faceted inhibition strategies to reverse
Insider Sell: Mountain Crest Acquisition Corp. V
04:12 PM EDT, 10/21/2022 (MT Newswires) -- Suying Liu, 10% Owner, Director, CEO and CFO, on October 19, 2022, sold 100,000 shares in Mountain Crest Acquisition Corp. V (MCAGU) for $1,000,000. Followin
Mountain Crest Acquisition to Merge With AUM Biosciences
06:33 AM EDT, 10/20/2022 (MT Newswires) -- Mountain Crest Acquisition Corp. V entered into a definitive business combination agreement with AUM Biosciences Pte. Ltd. The company said Thursday that t
Cancer Drugmaker Aum Biosciences to Go Public via SPAC Mountain Crest
AUM Biosciences to Become a Public Company via Merger With Mountain Crest Acquisition Corp. V
AUM Biosciences Pte. Ltd. ("AUM"), a clinical-stage biotechnology company, advancing a clinical stage pipeline designed to deploy multi-faceted inhibition strategies to reverse cancer resistance, and
Mountain Crest Acquisition Corp. V (NASDAQ:MCAG) Short Interest Update
Mountain Crest Acquisition Corp. V (NASDAQ:MCAG – Get Rating) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 70
Short Interest in Mountain Crest Acquisition Corp. V (NASDAQ:MCAG) Drops By 20.6%
Mountain Crest Acquisition Corp. V (NASDAQ:MCAG – Get Rating) was the target of a significant decrease in short interest in April. As of April 30th, there was short interest totalling 2,700 shares, a
Analysis
Price Target
No Data
